

Rapid deployment valve for aortic stenosis ups stroke risk

April 13 2018



(HealthDay)—For patients with aortic valve stenosis, treatment with a



rapid deployment valve (RDV) is associated with increased rates of newonset pacemaker implantation and disabling stroke, compared with conventional biological valves (CBVs), according to a study published in the April 3 issue of the *Journal of the American College of Cardiology*.

Stephan Ensminger, M.D., from Ruhr-University Bochum in Germany, and colleagues enrolled 22,062 patients who underwent isolated surgical aortic valve replacement using CBV or RDV between 2011 and 2015. Researchers used 1:1 propensity score matching to analyze baseline, procedural, and in-hospital outcome parameters for CBVs and RDVs. A total of 20,937 patients received a CBV, and 1,125 were treated with an RDV.

The researchers found that for patients treated with an RDV versus a CBV, there were significantly reduced times for procedure (150 versus 160 minutes), cardiopulmonary bypass (70 versus 83 minutes), and aortic cross clamp (44 versus 60 minutes; P

"In this large, all-comers database, the incidence of <u>pacemaker</u> <u>implantation</u> and disabling stroke was higher with RDVs, whereas no beneficial effect on in-hospital mortality was seen," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

More information: Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Copyright © 2018 HealthDay. All rights reserved.

Citation: Rapid deployment valve for aortic stenosis ups stroke risk (2018, April 13) retrieved 24 June 2024 from



https://medicalxpress.com/news/2018-04-rapid-deployment-valve-aortic-stenosis.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.